
New treatment options for bullous pemphigoid (BP), a prevalent autoimmune skin disease among the elderly, are emerging. Traditional management with systemic glucocorticoids poses risks, prompting the exploration of novel therapies. Rituximab, targeting B-lymphocytes, and Dupilumab, inhibiting IL-4 and IL-13, show efficacy in severe cases. Bertilimumab and AKST4290 targeting eosinophils, omalizumab reducing disease severity, and complement inhibitors like nomacopan offer promising results. IL-17 and IL-23 inhibitors, Fc receptor antagonists, topical treatments, and Janus kinase inhibitors are also under investigation. These advancements aim to enhance outcomes and reduce systemic corticosteroid-related toxicity in BP management.
Like
Save
Share